Antimicrobial Drug Resistance

1. Front Matter

   Pages i-xxi

   PDF

2. Gram Positive Bacterial Drug Resistance: Clinical

   1. Front Matter

      Pages 775-775

      PDF

   2. Resistance in Streptococcus pneumoniae

      • Lesley McGee, Keith P. Klugman

      Pages 777-790

   3. Antibiotic Resistance of Non-pneumococcal Streptococci and Its Clinical Impact

      • Nainee Desai, Judith Steenbergen, David E. Katz

      Pages 791-810

   4. Enterococcal Infections in Adults

      • Katherine Reyes, Marcus Zervos, Jisha John

      Pages 811-818

   5. Antimicrobial Resistance in Staphylococci aureus: Mechanisms of Resistance and Clinical Significance

      • Donald P. Levine, Jisha John

      Pages 819-826

   6. Resistance in Aerobic Gram-Positive Bacilli

      • David J. Weber, Melissa B. Miller, William A. Rutala

      Pages 827-840

3. Gram Negative Bacterial Drug Resistance: Clinical

   1. Front Matter

      Pages 841-841

      PDF

   2. Antibiotic Resistance in Neisseria

      • Margaret C. Bash, Kathryn A. Matthias

      Pages 843-865

   3. Mechanisms of Resistance in Haemophilus influenzae and Moraxella catarrhalis

      • Michael R. Jacobs

      Pages 867-888

   4. Enterobacteriaceae

      • David L. Paterson, Yohei Doi

      Pages 889-898

   5. Pseudomonas

      • Kamilia Abdelraouf, Vincent H. Tam

      Pages 899-922

   6. Acinetobacter baumannii and Acinetobacter spp.

      • Federico Perez, Robert A. Bonomo

      Pages 923-935

   7. Antimicrobial Resistance in Stenotrophomonas maltophilia: Mechanisms and Clinical Implications

      • Xian-Zhi Li, Jennifer Li

      Pages 937-958

   8. Antimicrobial Resistance of Shigella spp., Typhoid Salmonella, and Non-typhoid Salmonella

      • Herbert L. DuPont, Jean M. Whichard

      Pages 959-968

   9. Antimicrobial Resistance in Vibrio

      • Michael L. Bennish, Wasif A Khan, Sabeena Ahmed

      Pages 969-990

   10. Antimicrobial Resistance in Helicobacter and Campylobacter

       • Patrick F. McDermott, Francis Mégraud

       Pages 991-1006

   11. Antimicrobial Resistance of Anaerobic Bacteria

       • Itzhak Brook

       Pages 1007-1040

   12. Mycobacteria: Tuberculosis

       • Akos Somoskovi, Max Salfinger

       Pages 1041-1059

   13. Drug Resistance of Non-tuberculous Mycobacteria

       • Kathleen L. Horan, Gerard A. Cangelosi

       Pages 1061-1071

The two volumes included in Antimicrobial Drug Resistance, Second Edition is an updated, comprehensive and multidisciplinary reference covering the area of antimicrobial drug resistance in bacteria, fungi, viruses, and parasites from basic science, clinical, and epidemiological perspectives. This newly revised compendium reviews the most current research and development on drug resistance while still providing the information in the accessible format of the first edition. The first volume, Antimicrobial Drug Resistance: Mechanisms of Drug Resistance, is dedicated to the biological basis of drug resistance and effective avenues for drug development. With the emergence of more drug-resistant organisms, the approach to dealing with the drug resistance problem must include the research of different aspects of the mechanisms of bacterial resistance and the dissemination of resistance genes as well as research utilizing new genomic information. These approaches will permit the design of novel strategies to develop new antibiotics and preserve the effectiveness of those currently available. The second volume, Antimicrobial Drug Resistance: Clinical and Epidemiological Aspects, is devoted to the clinical aspects of drug resistance. Although there is evidence that restricted use of a specific antibiotic can be followed by a decrease in drug resistance to that agent, drug resistance control is not easily achieved. Thus, the infectious diseases physician requires input from the clinical microbiologist, antimicrobial stewardship personnel, and infection control specialist to make informed choices for the effective management of various strains of drug-resistant pathogens in individual patients. This 2-volume set is an important reference for students in microbiology, infectious diseases physicians, medical students, basic scientists, drug development researchers, microbiologists, epidemiologists, and public health practitioners.

• assays
• epidemiology
• public health
• antibiotics
• antivirals
• infectious disease
• pathogens
• antifungal
• drug resistance
• antibacterial drug resistance
• infectious diseases

• Treiber Therapeutics, Cambridge, USA

  Douglas L. Mayers

• Wayne State University School of Medicine, Detroit Medical Center, Detroit, USA

  Jack D. Sobel

• Canada Research Chair in Antimicrobial Resistance, Centre de recherche en Infectiologie, University of Laval, Quebec City, Canada

  Marc Ouellette

• Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, USA

  Keith S. Kaye

• Infection Control and Prevention Unit of Infectious Diseases, Assaf Harofeh Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel

  Dror Marchaim

Douglas L. Mayers is an infectious diseases specialist and is currently Chief Medical Officer (CMO) at Cocrystal Pharma. Dr. Mayers received his M.D. from University of Pennsylvania and has over 20 years of medical and clinical development experience spanning all phases of global clinical research and development and commercialization. He has worked with the United States Army Medical Research Institute of Infectious Diseases  to discover and develop drugs against the Ebola virus. He has also served as the Head of HIV Clinical Studies Program and Department of HIV Disease Prevention at the Walter Reed Army Institute of Research and Naval Medical Research Institute. Previously, he was the Chief Medical Officer and Executive Vice President at Idenix Pharmaceuticals, where he directed the Infectious Disease programs and led numerous regulatory filings globally, including successful advancement of several anti-HCV candidates to the clinical phase. Prior to Idenix, he was the International Head/Vice President of the Virology Therapeutic Area at Boehringer Ingelheim where he led Phase 1 through 4 clinical studies for HIV and hepatitis programs. In addition to his extensive expertise in the industry and in research, Dr. Mayers is well-known in the academic sphere and is the author of over 95 peer-reviewed publications and book chapters. 

Policies and ethics